Drug Profile

CDX 6512

Alternative Names: CDX-6512; SYNT-202

Latest Information Update: 26 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Codexis
Class Enzymes
Mechanism of Action Enzyme replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Homocystinuria
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Homocystinuria

Most Recent Events

11 Jun 2024 Syntis Bio plans to file an IND application with the US FDA in 2025
30 Apr 2024 Syntis Bio acquires CDX 6512 form Codexis, before April 2024
11 Feb 2022 CDX 6512 is available for licensing as of 11 Feb 2022 (Codexis website, November 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com